Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest		$ (14,914)	$ (17,892)	$ (33,426)	$ (40,106)
Net loss attributable to noncontrolling interest		4,087	3,355	7,387	7,638
Net loss - as reported, attributable to PAVmed Inc.		(10,827)	(14,537)	(26,039)	(32,468)
Series B Convertible Preferred Stock dividends – earned		(81)	(75)	(161)	(149)
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net loss attributable to PAVmed Inc. common stockholders		$ (10,908)	$ (14,612)	$ (33,696)	$ (32,617)
Weighted average common shares outstanding, basic		9,152,819	6,956,655	8,923,862	6,716,169
Weighted average common shares outstanding, diluted		9,152,819	6,956,655	8,923,862	6,716,169
Net loss attributable to PAVmed Inc. common stockholders, diluted	[1]	$ (1.19)	$ (2.10)	$ (3.78)	$ (4.86)
Net loss attributable to PAVmed Inc. common stockholders, basic	[1]		$ (2.10)		$ (4.86)

[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.